Finding new targets for immune therapy in cancer treatment
Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer
This study is looking for new ways to find special markers on cancer cells that can help your immune system fight melanoma and other cancers better, so that treatments can be more personalized and effective for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10862874 on NIH RePORTER |
What this research studies
This research focuses on identifying unconventional tumor-associated antigens (TAAs) that can be targeted by cytotoxic T lymphocytes (CTLs) to improve cancer immunotherapy. By exploring non-canonical sources of TAAs, such as those derived from RNA editing and proteasome splicing, the project aims to expand the range of potential targets for personalized cancer treatments. The methodology involves advanced proteomic techniques to discover these antigens, which could lead to the development of more effective therapies for patients with melanoma and other cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma or other cancers who may benefit from novel immunotherapy approaches.
Not a fit: Patients with cancers that do not express the identified unconventional TAAs may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in identifying unconventional TAAs, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Lizee, Gregory a — University of Tx Md Anderson Can Ctr
- Study coordinator: Lizee, Gregory a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.